Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30393777 | 0.94 | ELANE (0.43) | ELANETRPV1HRH1CCR3HDAC1 | |
| SCHEMBL24196156 | 0.94 | ELANE (0.43) | ELANETRPV1HRH1CCR3HDAC1 | |
| SCHEMBL25848866 | 0.83 | HDAC3 (0.43) | ELANEHRH1CCR3HDAC1HDAC6 | |
| SCHEMBL25848970 | 0.82 | EPHX2 (0.44) | ELANEHDAC1HDAC6EPHX2HDAC4 | |
| SCHEMBL25848857 | 0.81 | EPHX2 (0.45) | ELANEHDAC1HDAC6EPHX2BTK | |
| SCHEMBL24196672 | 0.80 | ELANE (0.40) | ELANETRPV1HDAC1HDAC6EPHX2 | |
| SCHEMBL24196149 | 0.77 | HDAC3 (0.44) | ELANEHRH1CCR3HDAC1HDAC6 | |
| SCHEMBL25848811 | 0.76 | SMN1; SMN2 (0.51) | HRH1CCR3HDAC1HDAC6EPHX2 | |
| SCHEMBL25848762 | 0.75 | HDAC1 (0.46) | HRH1CCR3HDAC1HDAC6EPHX2 | |
| SCHEMBL25304798 | 0.74 | NAMPT (0.41) | ELANETRPV1HDAC1HDAC6EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | ELANE 4457/4885TRPV1 330/4885HRH1 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.